4D Molecular Therapeutics filed the paperwork for a $100 Million IPO on 9/30/19. The Emeryville, CA based company is focused on developing genetic therapies for both rare and large market diseases. The company will trade on NASDAQ under the symbol “DDDD.”
4D currently has six treatments in development. The company expects to initiate our first clinical trials for three product candidates in 2020. The candidates include treatments for Fabry disease, X-linked Retinitis Pigmentosa (XLRP), and Cystic Fibrosis.
Current investors include Pfizer Ventures, Berkeley Catalyst Fund, and Viking Global Investors. 4D has partnered with Roche and AstraZeneca on several projects.
The company believes its Therapeutic Vector Evolution platform allows it to overcome limitations that other delivery vectors have encountered. The company's preclinical data from non-human primates (NHPs) and human cell models, including preclinical head-to-head comparisons with conventional AAVs, has yielded observations that their precision gene therapy AAVs were well-tolerated and achieved enhanced delivery, increased transgene expression, reduced immunogenicity and/or improved antibody resistance when compared to conventional AAVs.
